These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 21848464)

  • 1. Development of antiretroviral drug resistance.
    Wainberg MA; Zaharatos GJ; Brenner BG
    N Engl J Med; 2011 Aug; 365(7):637-46. PubMed ID: 21848464
    [No Abstract]   [Full Text] [Related]  

  • 2. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

  • 3. New antiretroviral agents and the complexity of treatment practices.
    Smith D
    J HIV Ther; 2008 Jun; 13(2):25-6. PubMed ID: 18953270
    [No Abstract]   [Full Text] [Related]  

  • 4. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
    AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
    Deeks SG; Hoh R; Neilands TB; Liegler T; Aweeka F; Petropoulos CJ; Grant RM; Martin JN
    J Infect Dis; 2005 Nov; 192(9):1537-44. PubMed ID: 16206068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
    Metzner KJ; Allers K; Rauch P; Harrer T
    AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral drug resistance and fitness.
    Quiñones-Mateu ME; Moore-Dudley DM; Jegede O; Weber J; J Arts E
    Adv Pharmacol; 2008; 56():257-96. PubMed ID: 18086415
    [No Abstract]   [Full Text] [Related]  

  • 10. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia.
    Jamjoom GA; Azhar EI; Madani TA; Hindawi SI; Bakhsh HA; Damanhouri GA
    Saudi Med J; 2010 Sep; 31(9):987-92. PubMed ID: 20844809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detectable viral loads and slow development of resistance.
    Gadd C
    IAPAC Mon; 2005 Oct; 11(10):295-6. PubMed ID: 16673496
    [No Abstract]   [Full Text] [Related]  

  • 12. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 13. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
    Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
    AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
    [No Abstract]   [Full Text] [Related]  

  • 14. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program.
    Sutthent R; Arworn D; Kaoriangudom S; Chokphaibulkit K; Chaisilwatana P; Wirachsilp P; Thiamchai V; Sirapraphasiri T; Tanprasertsuk S
    J Clin Virol; 2005 Dec; 34(4):272-6. PubMed ID: 16286051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to novel drug classes.
    Marcelin AG; Ceccherini-Silberstein F; Perno CF; Calvez V
    Curr Opin HIV AIDS; 2009 Nov; 4(6):531-7. PubMed ID: 20048722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic resistance testing in HIV-infected pregnant women in an urban setting.
    Shah SS; Crane M; Monaghan K; McGowan JP
    Int J STD AIDS; 2004 Jun; 15(6):384-7. PubMed ID: 15186583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
    Duval X; Descamps D; Breton G; Darmon S; Ecobichon JL; Delarue S; Peytavin G; Leport C; Vildé JL; Brun-Vézinet F
    Antivir Ther; 2005; 10(1):197-9. PubMed ID: 15751779
    [No Abstract]   [Full Text] [Related]  

  • 20. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan.
    Chang SY; Chen MY; Lee CN; Sun HY; Ko W; Chang SF; Chang KL; Hsieh SM; Sheng WH; Liu WC; Wu CH; Kao CL; Hung CC; Chang SC
    J Antimicrob Chemother; 2008 Mar; 61(3):689-93. PubMed ID: 18227088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.